Advances in Diagnosis and Management of Cutaneous Adverse Drug Reactions. Current and Future Trends

Section I. Introduction.- 1. Introduction: Classification, Terminology, Epidemiology and Etiology of Cutaneous Adverse Drug Reactions.- Section II. Pathomechanisms of Cutaneous Adverse Drug Reactions.- 2. Immunology of Cutaneous Adverse Drug Reactions.- 3. Pharmacogenomics and Cutaneous Adverse Drug Reactions.- 4 Viral Reactivation in Cutaneous Adverse Drug Reactions.- 5. Using Technology to Learn About Immunology of Cutaneous Adverse Drug Reactions.- Section III. Clinical Perspectives of Cutaneous Adverse Drug Reactions.- 6. Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (Epithelial Necrolysis).- 7. Drug Reaction with Eosinophilia and Systemic Symptoms.- 8. Acute Generalized Exanthematous Pustulosis.- 9. Urticarial Reactions to Drugs.- 10. Dermatological Adverse Events from Cancer Treatments.- 11. Cutaneous Adverse Drug Reactions in Pediatric Population.- 12. Cutaneous Drug Reactions in the Elderly.- 13. Cutaneous Adverse Drug Reactions in Human Immunodeficiency Virus Patients.- 14. Cutaneous Adverse Drug Reactions from Anti-Tuberculosis Treatment.- Section IV. Approach to the Patient with a Cutaneous Adverse Drug Reaction.- 15. Practical Approach to Diagnosis and Management of Cutaneous Adverse Drug Reactions.- 16. Histopathology of Severe Drug Eruptions.- 17. Evaluation of Drug Safety Literature: A Guide for the Practicing Dermatologist.- 18. In vitro and in vivo tests in Cutaneous Adverse Drug Reactions.- 19. Pharmacovigilance of Cutaneous Adverse Drug Reactions.- Section V. Epilogue.- 20. Future Directions and Unmet Research Needs in Cutaneous Adverse Drug Reactions.- 21. Atlas of Cutaneous Adverse Drug Reactions.

This resource guides prescribers, pharmacists, and regulators with an update on the recent expansion of basic and clinical knowledge that forms a framework for understanding cutaneous reactions. This understanding will lead, in turn, to better outcomes and decisions in treatment and management, both in the clinic and in the life cycle of drug development.

The skin is a common target for adverse drug events and even mild rashes can be part of life-threatening syndromes. Patients and practitioners often face important decisions about therapy after a drug eruption, including treatment, cross-reactivity with future pharmaceuticals, genetic considerations and dealing with long-term sequelae after a reaction. An international team of experts and leaders in the field share their story and insights into the scientific details and relevant clinical context.

Dr. Neil H. Shear is a University of Toronto Professor of Medicine (Internal Medicine, Dermatology, Clinical Pharmacology and Toxicology) and Head of the Drug Safety Clinic at Sunnybrook Health Sciences Centre. He is the president of the Canadian Dermatology Association and past-president of the Canadian Society for Clinical Pharmacology and the Canadian Dermatology Foundation. He chaired the University Division of Dermatology from 2001 to 2017.

His research is in all aspects of Drug Safety. He has published over 350 peer-reviewed papers, authored/co-authored over 60 textbook chapters, and has served on many journal editorial boards. He is currently the Editor of Litt's Drug Eruption Reference Manual. He has recently been awarded the Practitioner-of-the-Year award from the Canadian Dermatology Association.

Dr. Roni P. Dodiuk-Gad is the Vice-head of the Dermatology Department, Emek Medical Center, an Assistant Professor in the Bruce Rappaport Faculty of Medicine, Technion - Institute of Technology, Israel and a Research Fellow at the University of Toronto, Canada. Her research interests are primarily adverse cutaneous drug reactions and Darier disease. She conducted 3 years of clinical fellowship in `Advanced Medical Dermatology' under the supervision of Professor Neil H. Shear and upon completion became his research fellow. She has been interested in the topic of adverse cutaneous drug reactions since the beginning of her residency in dermatology in 2003; she was a member of the RegisCAR research team, has published many book chapters on the topic and was in the organizing committee of recent important conferences on the topic. She received numerous academic awards; in 2015 in the 23rd World Congress of Dermatology, she was invited to give a Rising Star Talk and in 2018, she was chosen as one of the 40 most promising young graduated of the Technion - Institute of Technology, Israel.